The effect of anti-tumour necrosis factor   treatment on the antibody response to influenza vaccination

Gelinck, L. B. S.; Bijl, A.E. van der; Beyer, Walter; Visser, Leo G.; Huizinga, Tom W J; Hogezand, R. A. van; Rimmelzwaan, G.F.; Kroon, F.P.

doi:10.1136/ard.2007.077552

Cited by 164 publications

(103 citation statements)

References 15 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, when patients are receiving immunosuppressive therapies with combined thiopurines and anti-TNF agents, serologic responses to vaccines are impaired ( 22,23,(43)(44)(45)(46)(47)(48)(49)(50)(51). Nonetheless, even a blunted vaccination response is thought to be of benefi t ( 52 ) and thus recommendations for infl uenza vaccination with inactivated vaccine continue to be broadly applicable to all patients, regardless of immunosuppression status ( 13,53 ).…”

Section: Summary Of Evidencementioning

confidence: 99%

ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease

Farraye

Melmed

Lichtenstein

et al. 2017

American Journal of Gastroenterology

393

421

View full text Add to dashboard Cite

Recent data suggest that infl ammatory bowel disease (IBD) patients do not receive preventive services at the same rate as general medical patients. Patients with IBD often consider their gastroenterologist to be the primary provider of care. To improve the care delivered to IBD patients, health maintenance issues need to be co-managed by both the gastroenterologist and primary care team. Gastroenterologists need to explicitly inform the primary care provider of the unique needs of the IBD patient, especially those on immunomodulators and biologics or being considered for such therapy. In particular, documentation of up to date vaccinations are crucial as IBD patients are often treated with long-term immune-suppressive therapies and may be at increased risk for infections, many of which are preventable with vaccinations. Health maintenance issues addressed in this guideline include identifi cation, safety and appropriate timing of vaccinations, screening for osteoporosis, cervical cancer, melanoma and non-melanoma skin cancer as well as identifi cation of depression and anxiety and smoking cessation. To accomplish these health maintenance goals, coordination between the primary care provider, gastroenterology team and other specialists is necessary. of evidence, we entered data from the papers of highest evidence into the GRADE program (accessible at http://www.gradepro.org ). Th e recommendation statements from this guideline are shown in Table 1 . Summary statements, when listed, are designed to be descriptive in nature without associated evidence-based ratings. VACCINATIONSRecent data suggest that IBD patients do not receive preventive services at the same rate as general medical patients ( 2 ). Members of the gastroenterology team are oft en the only clinicians that a patient with IBD will see. As such, it is incumbent upon gastroenterologists to take a proactive role in the health care needs of their IBD patients ( 3-5 ). It is crucial to clarify with the patient the limits of the specialist's responsibilities and delegate routine health care issues to the primary care clinician. It is equally important to educate the primary care clinician to the unique health maintenance needs of the IBD patient, especially those on immunomodulators and biologic agents. Although it appears that both primary care clinicians and gastroenterologists are hesitant to take ownership of vaccinations ( 6-8 ), it is reasonable ( 9 ) that vaccination recommendations be the responsibility of the treating gastroenterologist, but the actual delivery/administration of these vaccines may be a shared responsibility ( 10-13 ). Communicating specifi c recommendations to the primary care team in a concise fashion are needed. Consider empowering the patient by giving written recommendations to bring to their primary care physician. Clinicians sharing an electronic medical record should use this platform to send recommendations to the referring clinician.Patients with IBD are oft en treated with long-term immunesuppressive therapies and may t...

show abstract

Section: Summary Of Evidencementioning

confidence: 99%

ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease

Farraye

Melmed

Lichtenstein

et al. 2017

American Journal of Gastroenterology

393

421

View full text Add to dashboard Cite

show abstract

“…Numerous authors state similar efficiency of vaccination for RA patients and healthy volunteers, without any significant influence of DMARD's or biological therapy on the humoral response (Elkayam 2006;Rahier et al 2010). A few recent studies reported a mild or severe impairment of the humoral response after administration of biological therapy in patients suffering from RA (Gelinck et al 2008;van Assen et al 2010).…”

Section: Discussionmentioning

confidence: 99%

Influenza Vaccination in Autoimmune Rheumatic Disease Patients

Milanovic

Stojanovich

Djoković

et al. 2013

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

“…87,88 For example, some studies have suggested that patients on TNF inhibitors may have a slightly decreased immune response to influenza vaccine. [89][90][91] Specific data for patients with IBD are very scarce. Some authors have evaluated the serological response to influenza vaccine in patients with IBD and observed that those receiving anti-TNF therapy were less likely to be seroprotected.…”

Section: What Factors Affect the Efficacy Of Hbv Vaccination In Ibd Pmentioning

confidence: 99%

Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease

Gisbert

Chaparro

Esteve

2011

Alimentary Pharmacology &Amp; Therapeutics

105

View full text Add to dashboard Cite

The effect of anti-tumour necrosis factor treatment on the antibody response to influenza vaccination

Abstract: The antibody response to influenza vaccination in patients treated with anti-TNF is only modestly impaired. The proportion of patients that achieves a protective titre is not significantly diminished by the use of TNF blocking therapies.

Cited by 164 publications

References 15 publications

ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease

ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease

Influenza Vaccination in Autoimmune Rheumatic Disease Patients

Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease

Contact Info

Product

Resources

About